A randomised, double blind, double dummy, multicentre phase III study comparing the efficacy of budesonide/formoterol (Symbicort® forte Turbuhaler®) and oral prednisolone + formoterol (Oxis® Turbuhaler) during two weeks, in COPD patients with an acute exacerbation, followed by twelve weeks open follow up period with budesonide/formoterol (Symbicort forte Turbuhaler) - SPACE
- Registry ID
- EUCTR2005-001090-10
- Source registry
- EUCTR
- Status
- Completed
- Phase
- PHASE3
- Sponsor
- AstraZeneca AB, AstraZeneca Sverige
- Start date
- 2005-06-28
- Completion date
- 2007-09-07
- Last update
- 2026-08-16
Conditions
- Chronic Obstructive Pulmonary Disease (COPD).
Summary
To assess if a double standard dose of Symbicort forte Turbuhaler during two weeks is as effective as an oral course of prednisolone + Oxis Turbuhaler (during two weeks) for the treatment of an acute exacerbation of Chronic Obstructive Pulmonary Disease (COPD).
Locations
- , , Sweden
- , , Denmark
- , , Finland
- , , Germany
View on source registry